- Ziggma
- Posts
- 🗞️ Amazon 🤝 OpenAI
🗞️ Amazon 🤝 OpenAI
Big Moves Decoded: IDXX, KVUE, and more!
In partnership with
Market Performance
S&P 500: 6,851.97 ⬆️ 0.17%
Nasdaq: 23,834.72 ⬆️ 0.46%
Dow Jones: 47,336.68 ⬇️ 0.48%
Amazon Inks $38 Billion Deal With OpenAI
OpenAI has signed a massive $38 billion agreement with Amazon Web Services—marking the ChatGPT creator's first major contract with AWS and a clear signal of its independence from its longtime partner, Microsoft.
The deal grants OpenAI immediate access to hundreds of thousands of Nvidia GPUs across U.S. data centers, with plans to expand over the next seven years.
Amazon's (AMZN) stock surged 4% to a record high on the news, capping its best two-day rally since November 2022.
Until this year, OpenAI had an exclusive cloud relationship with Microsoft, which has invested $13 billion in the company since 2019.
But as Microsoft's preferential status expired last week, OpenAI wasted no time diversifying its infrastructure partnerships across the hyperscale cloud providers.
Source: App Economy Insights
For AWS, this is a major strategic win. Despite leading the cloud market, AWS recently reported slower growth than Microsoft Azure and Google Cloud.
Landing OpenAI—the hottest name in AI—validates AWS's AI infrastructure capabilities and helps close the perception gap with rivals who've been making bigger AI headlines.
Our Takeaway
OpenAI is methodically building the foundation for an eventual IPO by reducing dependency on any single cloud provider and locking in massive long-term capacity.
Meanwhile, Amazon just proved it can compete for the most valuable AI workloads, even with Microsoft and Google aggressively courting the same customers.
The Smartest Free Crypto Event You’ll Join This Year
Curious about crypto but still feeling stuck scrolling endless threads? People who get in early aren’t just lucky—they understand the why, when, and how of crypto.
Join our free 3‑day virtual summit and meet the crypto experts who can help you build out your portfolio. You’ll walk away with smart, actionable insights from analysts, developers, and seasoned crypto investors who’ve created fortunes using smart strategies and deep research.
No hype. No FOMO. Just the clear steps you need to move from intrigued to informed about crypto.
Market Overview 📈
Monday's session delivered a classic narrow-breadth rally, with AI and semiconductor stocks masking widespread weakness across the broader market.
Over 80% of S&P 500 stocks closed lower even as the Nasdaq pushed into positive territory.
Microsoft has disclosed that it has secured export licenses to ship Nvidia chips to the United Arab Emirates, with total UAE investment now reaching $15.2 billion through 2029.
Chipmakers rallied in sympathy, with Micron Technology leading the sector up nearly 5% and Nvidia advancing 2%. The semiconductor ETF SMH climbed almost 1%.
However, the market's narrow leadership remains a persistent concern, as more than 300 S&P 500 stocks finished in the red, with NYSE decliners outnumbering advancers by more than 2 to 1.
This weak breadth has characterized October's gains, even as the AI rally pushed major indices higher for the month.
Third-quarter earnings continue showing resilience, with over 80% of the 300-plus companies reporting so far beating expectations.
Bank of America notes earnings growth is tracking 12% year-over-year, marking the fourth consecutive quarter of double-digit expansion.
The ISM manufacturing index disappointed at 48.7%, missing estimates and slipping further into contraction territory, though employment showed modest improvement, and price pressures eased significantly.
Stock Moves Deciphered 📈
IDEXX Laboratories (IDXX) ⬆️ ~15%
IDEXX surged after delivering robust Q3 earnings that exceeded expectations and raising full-year financial guidance.
The veterinary diagnostics leader benefited from strong demand across its entire product portfolio, with management expressing confidence in sustaining this growth momentum.
Revenue growth accelerated in both diagnostic and software segments, while international expansion continues driving incremental gains.
Kenvue (KVUE) ⬆️ ~15%
Kenvue shares jumped following Kimberly-Clark's announcement of a $48.7 billion cash and stock acquisition offer.
The deal represents a significant premium to Kenvue's trading price and is expected to create a consumer health powerhouse combining iconic brands like Tylenol and Motrin with Kimberly-Clark's personal care portfolio.
Incyte Corporation (INCY) ⬆️ ~8.5%
Incyte rallied after posting better-than-expected Q3 results and sharing promising clinical trial data for its oncology pipeline.
The biopharmaceutical company's cancer drug programs showed encouraging efficacy signals, boosting investor confidence in future revenue growth beyond its current commercial products.
Management highlighted strong prescription trends for key marketed therapies and outlined accelerated development timelines for late-stage candidates.
Headlines You Can't Miss 👀
💰 Berkshire Hathaway reported 34% jump in operating earnings to $13.5 billion in Q3, driven by 200% surge in insurance underwriting income; cash reserves hit record $381.6 billion.
💸 Microsoft disclosed a total investment of $15.2 billion in the UAE through 2029 after securing export licenses to ship Nvidia chips, including an equivalent of 60,400 additional A100 GPUs in advanced GB300 models.
📊 ISM manufacturing index fell to 48.7% in October, missing the 49.3% estimate and dropping further into contraction as production weakened, while employment improved modestly and prices cooled.
🏦 San Francisco Fed President Mary Daly advocated cautious approach for December rate decision, noting labor market softness without weakness while inflation runs above 2% target.
🛒 Costco has been named a top pick by Oppenheimer, with a $1,050 target price reflecting a 15% upside, citing a superior value proposition and market share gains in a mixed consumer spending environment.
💼 Wells Fargo raised JPMorgan price target to $350 citing best-in-class returns and undervalued price-to-book, calling the bank "Nvidia of Banking" after peak tech modernization spending.
Trending Stocks 📊
Iren (IREN) ⬆️ ~ 11.5%
Iren rallied sharply on its landmark $9.7 billion, five-year agreement with Microsoft to provide Nvidia GB300 GPU access.
The deal validates Iren's positioning as a leading AI cloud service provider and opens access to hyperscaler customers across its 3GW secured North American power portfolio.
ON Semiconductor (ON) ⬆️ ~4%
ON Semiconductor advanced after beating Q3 estimates with adjusted earnings of $0.63 per share on revenue of $1.55 billion, surpassing analyst forecasts of $0.59 and $1.52 billion.
The results demonstrated resilient demand for the company's automotive and industrial semiconductor solutions.
Moderna (MRNA) ⬇️ ~8.5%
Moderna continued its downward slide as investors grapple with concerns about post-pandemic growth ahead of the company's quarterly earnings report.
The stock has struggled with market uncertainty about demand for updated COVID vaccines and the timeline for commercializing its broader mRNA pipeline.
What’s Next?
Key market and macro news 👇
💊 Pharmaceutical giant Pfizer is scheduled to report its quarterly earnings. Analysts predict a decrease in earnings per share compared to the same quarter in the previous year.
🚗 Ride-sharing and food delivery company Uber is expected to report its quarterly earnings before the market opens.
📊 The U.S. trade balance for August will be released, providing insight into the country's trade deficit or surplus.
👨💻 The Job Openings and Labor Turnover Survey (JOLTS) for October will be released, indicating the health of the labor market.
🏭 The factory orders report for October will be released, which will provide data on the manufacturing sector.
👟 The Redbook Index will be released, which tracks sales growth at large U.S. retailers.
Chart of the Day
Meme of the Day
Great investing starts with great information.
Forward The Market Scoop to anyone who wants to stay ahead of the market through a pertinent and entertaining newsletter format.
DISCLAIMER: None of this is financial advice. The newsletter is strictly educational and is not investment advice or a solicitation to buy or sell assets or make financial decisions. Please exercise caution and conduct your own research.